Helen X Chen

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint IGF-1R as an anti-cancer target--trials and tribulations
    Helen X Chen
    National Cancer Institute, Bethesda, MD 20892, USA
    Chin J Cancer 32:242-52. 2013
  2. doi request reprint Adverse effects of anticancer agents that target the VEGF pathway
    Helen X Chen
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20851, USA
    Nat Rev Clin Oncol 6:465-77. 2009
  3. doi request reprint Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    Nilofer S Azad
    Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 26:3709-14. 2008
  4. ncbi request reprint Expanding the clinical development of bevacizumab
    Helen X Chen
    Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 9:27-35. 2004
  5. doi request reprint Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
    Shivanni Kummar
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Drug Discov 9:843-56. 2010
  6. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
  7. ncbi request reprint Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301
    Helen X Chen
    Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:3354-60. 2006
  8. ncbi request reprint Strategies for optimizing combinations of molecularly targeted anticancer agents
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 5:649-59. 2006
  9. ncbi request reprint Clinical development of antisense oligonucleotides as anti-cancer therapeutics
    Helen X Chen
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 75:621-36. 2003

Detail Information

Publications9

  1. doi request reprint IGF-1R as an anti-cancer target--trials and tribulations
    Helen X Chen
    National Cancer Institute, Bethesda, MD 20892, USA
    Chin J Cancer 32:242-52. 2013
    ..While IGF-1R remains a valid target for selected tumor types, identification of predictive markers and rational combinations will be critical to success in future development...
  2. doi request reprint Adverse effects of anticancer agents that target the VEGF pathway
    Helen X Chen
    Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20851, USA
    Nat Rev Clin Oncol 6:465-77. 2009
    ..This Review examines the toxicity profiles of anti-VEGF antibodies and small-molecule inhibitors. The potential mechanisms of the adverse effects, risk factors, and the implications for selection of patients and management are discussed...
  3. doi request reprint Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
    Nilofer S Azad
    Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 26:3709-14. 2008
    ..Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects...
  4. ncbi request reprint Expanding the clinical development of bevacizumab
    Helen X Chen
    Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Oncologist 9:27-35. 2004
    ..Treatment regimens being examined include bevacizumab alone and in combination with conventional chemotherapy, radiation, immune therapy, and biologically targeted agents...
  5. doi request reprint Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
    Shivanni Kummar
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Drug Discov 9:843-56. 2010
    ....
  6. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  7. ncbi request reprint Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301
    Helen X Chen
    Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:3354-60. 2006
    ....
  8. ncbi request reprint Strategies for optimizing combinations of molecularly targeted anticancer agents
    Janet E Dancey
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA
    Nat Rev Drug Discov 5:649-59. 2006
    ..Issues that pose challenges to the rational preclinical and clinical evaluation of such combinations will be described, and possible approaches to overcoming these challenges will be discussed...
  9. ncbi request reprint Clinical development of antisense oligonucleotides as anti-cancer therapeutics
    Helen X Chen
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    Methods Mol Med 75:621-36. 2003